Related Experiment Video
Updated: Apr 14, 2026

Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients
Published on: September 25, 2018
Pembrolizumab offers improved outcomes for advanced non-small cell lung cancer patients and is well-tolerated. High programmed death-ligand 1 (PD-L1) expression (≥50%) predicts better treatment efficacy.
Area of Science:
- Oncology
- Immunotherapy
- Clinical Trials
Background:
- Advanced non-small cell lung cancer (NSCLC) presents significant treatment challenges.
- Immunotherapy has emerged as a promising treatment modality for NSCLC.
More Related Videos
10:29Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence
Published on: August 14, 2019
07:42Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients
Published on: February 7, 2021
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against...
Treatment Resistent Cancers
Tumor Immunotherapy
Treatment Resistant Cancers